Alessio Cantore received a Ph.D. in cellular and molecular biology in 2013 from the Open University, London, and “Vita-Salute San Raffaele” University under the supervision of Prof. Luigi Naldini, Prof. Thierry VandenDriessche (Free University of Brussels), and Prof. Maria Grazia Roncarolo. He has made important contributions to the field of liver-directed gene therapy by evaluating the efficacy and safety of systemic lentiviral vector administration in different experimental models and engineering vectors with enhanced biological properties, reduced immunogenicity, and high potency. He has published 24 original research articles and 7 review articles on peer-reviewed international scientific journals (h-index: 19) and is the inventor of >10 patents. He has been invited to speak at several international conferences and is a recipient of various awards, including the 2018 Young Investigator Award from the European Society of Gene and Cell Therapy and several Excellence in Research Awards from the American Society of Gene and Cell Therapy. Since 2017, he has served as Assistant Professor of Tissue Biology at “Vita-Salute San Raffaele” University, and since 2020, he is Group Leader at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget). He is also a scientific co-founder of GeneSpire, an innovative Start-up company aimed at developing liver-directed gene therapy for inherited metabolic diseases. He has recently been awarded a consolidator grant from the European Research Council (ERC).